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ABSTRACT
Delayed graft function (DGF) is defined as the need for dialysis within 7 days following kidney transplantation (KTx).
DGF is associated with increased costs, higher risk for acute rejection and decreased long-term graft function. Renal
ischaemia/reperfusion (I/R) injury plays a major role in DGF occurrence. Single nucleotide polymorphisms (SNPs) in certain
genes may aggravate kidney susceptibility to I/R injury, thereby worsening post-transplant outcomes. The present article
proposes an extensive review of the literature about the putative impact of donor or recipient SNPs on DGF occurrence in
kidney transplant recipients (KTRs). Among 30 relevant PubMed reports, 16 articles identified an association between
18 SNPs and DGF. These polymorphisms concern 14 different well-known genes and one not-yet-identified gene located on
chromosome 18. They have been categorized into five groups according to the role of the corresponding proteins in I/R
cascade: (i) oxidative stress, (ii) telomere shortening, (iii) chemokines, (iv) T-cell homeostasis and (v) metabolism of anti-
inflammatory molecules. The remaining 14 studies failed to demonstrate any association between the studied SNPs and the
occurrence of DGF. A better understanding of the genetic susceptibility to renal I/R injury may help prevent DGF and
improve clinical outcomes in KTRs.
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INTRODUCTION
Delayed graft function (DGF) is a manifestation of acute kidney
injury related to kidney transplantation (KTx). It has been defined
as the requirement for dialysis within 7 days following KTx [1].
DGF causes increased risk for acute rejection (AR) and has been
associated with poor long-term graft outcomes and additional
costs [2]. Various immunological and non-immunological factors
have been linked to DGF, including donor age, Human Leucocyte
Antigen (HLA) compatibility, cold and warm ischaemia time,
immunosuppressive regimen of induction and maintenance and
dialysis vintage. Expanded criteria donors (ECDs) in KTx lead to
an increased risk for DGF [3]. Still, the incidence of DGF in ECD re-
cipients has progressively decreased over time from 35.2% in
2003 to 29.6% in 2011 in the USA, probably related to a better
understanding of the donor risk profile along with improved allo-
graft selection [3]. Cardiac death donors have also shown a higher
rate of DGF [4]. Indeed, renal ischaemia/reperfusion (I/R) injury
plays a critical role in DGF. I/R injury occurs when the blood
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supply to an organ is transiently disrupted and subsequently
restored [5]. KTx necessarily conveys renal I/R, which prompts ac-
tive preclinical and clinical research focusing on the prevention
and/or attenuation of graft damage [6–9].
Besides the role of extrarenal factors in DGF, one may specu-
late that intrarenal characteristics may predispose the kidney
allograft to injury. Global gene expression profiling captures
such a complex process, thereby highlighting the putative im-
plications of particular genes and metabolic cascades in renal
I/R injury and DGF [8, 10, 11]. DGF-associated genes are impli-
cated in pathways of oxidative stress, vasospasm, cytokine sig-
nalling, endothelial and epithelial cell injury, as well as innate
and adaptive immunity. Some of these genes harbour single nu-
cleotide polymorphisms (SNPs). By definition, SNPs correspond
to the variation of only one base pair in one given gene, which
may cause significant changes in the expression and/or activity
of the corresponding protein. By extension, polymorphisms cor-
respond to the coexistence of several distinct alleles in one
given gene in a population. The haplotype is the combination of
SNPs at multiple linked loci that are usually transmitted as a
group from parent to child.
In 2008, Kru¨ger et al. [12] summarized the literature about
genetic polymorphisms and the fate of the transplanted organ,
including the impact of both immunological and non-
immunological cascades on graft survival, AR and the occur-
rence of chronic allograft nephropathy. Our present review
focuses on DGF and aims to systematically detail the published
reports about potential associations between polymorphisms in
kidney donors and recipients and the occurrence of DGF.
MATERIALS ANDMETHODS
We systematically searched PubMed for articles published from
the database’s inception date to May 2017 using the following
keywords: ‘delayed graft function’ or ‘DGF’ or ‘ischaemia-
reperfusion’ and ‘kidney’ or ‘renal’ and ‘allograft’ or ‘transplant-
ation’ and ‘polymorphisms’ or ‘SNP’. Furthermore, we reviewed
the papers referenced in the ‘PubMed-related’ articles to iden-
tify additional candidate studies for which full-text English-lan-
guage articles were available. Bibliographic references of both
original investigations and review articles were then scruti-
nized. We included studies with the following quality criteria:
(i)  50 patients (kidney recipients, donors or both), (ii) well-
defined evaluation of DGF occurrence and outcomes and (iii)
polymorphisms in molecules involved in I/R-related processes.
The articles that did not reach these criteria were excluded.
Careful attention was given to the genetic background of
studied populations.
RESULTS
We found 45 relevant articles in the PubMed database using the
above-defined keywords. Four of these were excluded because
the studied polymorphisms concerned genes coding for pro-
teins involved in pharmacodynamics and pharmacokinetics of
immunosuppressive drugs. Eleven articles were excluded be-
cause they did not strictly focus on DGF. Among the remaining
30 articles, 16 found an association between 18 polymorphisms
and DGF (Table 1). These polymorphisms were present in 11 dif-
ferent well-known genes and in one not-yet-identified gene
located on chromosome 18. We categorized them into five
groups according to the role of the corresponding proteins in
I/R cascade: (i) oxidative stress, (ii) telomere shortening, (iii)
chemokines, (iv) T-cell homeostasis and (v) metabolism of
anti-inflammatory molecules. The remaining 14 studies failed
to demonstrate any association between the studied poly-
morphisms and the occurrence of DGF. These data are summar-
ized in Table 2.
Oxidative stress
GSTM1, GSTM3, GSTT1, GSTP1 and MnSOD polymorphisms.
Glutathione S-transferases (GSTs) and manganese superoxide
dismutase (MnSOD) contribute to protection against xenobiotic
compounds, including immunosuppressive drugs in kidney
transplant recipients (KTRs). GSTs and MnSOD are also involved
in antioxidative reactions and in the regulation of apoptosis
through direct protein–protein interactions. At the time of kid-
ney reperfusion, GSTs and MnSOD are rapidly induced to scav-
enge reactive oxygen species (ROS) and prevent ROS-associated
damage [13, 14]. St. Peter et al. [13] genotyped 229 British KTRs
with  24 h of cold ischaemia and 104 of their respective donors.
They focused on the polymorphisms of three classes of GSTs
and MnSOD: GSTM1*A, GSTM1*B, GSTT1*1, GSTP1*A, GSTP1*B,
GSTP1*C, GSTP1*D, MnSOD aa14Ala and MnSOD aa14Val. In kid-
ney donors, the presence of homozygous GSTM1*B or heterozy-
gous GSTM1*B with GSTM1 null or GSTM1*A was associated with
a lower risk for DGF. In KTRs, no association was found between
any enzyme polymorphism and DGF occurrence [13]. Singh et al.
[14] enrolled 223 controls and 273 North Indian KTRs to study
the impact of polymorphisms in three GST isoenzyme genes
(GSTM1, GSTM3, GSTT1 and GSTP1) on early graft function. The
authors observed that recipients with the rs1695 genotype GG of
GSTP1 were at higher risk of DGF [14].
rs1001179 (-262C/T) polymorphism in the CATALASE gene.
Catalase is an intracellular antioxidant enzyme effective in pro-
tecting cells from hydrogen peroxide [41]. Catalase is crucial in
attenuating graft I/R injuries in the immediate phase after KTx
[42, 15]. Dutkiewicz et al. [15] studied the impact of the -262 C/T
(rs1001179) polymorphism in CATALASE on renal function out-
comes in 187 Polish KTRs. The T allele was associated with a
reduced risk of DGF, with increased blood levels of catalase
found in the -262 T patients [15].
NADPH oxidase p22(phox) C242T polymorphism. p22(phox) is a
polymorphic subunit of NAD(P)H oxidase that plays a critical
role in its activation and stabilization. NAD(P)H oxidase is
involved in the production of superoxide that triggers the in-
flammation in ischaemic kidneys [43, 16]. Mandegary et al. [16]
enrolled 196 Iranian donor–recipient pairs to investigate the as-
sociation between donors’ and recipients’ NADPH oxidase
p22(phox) C242T polymorphism and AR, DGF and blood pressure
levels in KTRs. Recipient’s p22(phox) 242 T allele (CTþTT) was
found to be a major risk factor for DGF, most probably via the
overproduction of superoxide at the time of I/R [16].
Telomere shortening
A significant shortening in telomere length has been reported
in ischaemic kidneys, which suggests I/R-accelerated tissue
senescence [44]. Shorter telomeres have also been associated
with a lower immune response [45]. Polymorphisms in hTERT,
BICD1 and chromosome 18 interfere with telomere shortening.
Kłoda et al. studied rs2735940 hTERT, rs2630578 BICD1 and
rs7235755 in chromosome 18 polymorphisms in 119 Polish kid-
ney allografts [17] and corresponding recipients [18] as well as
in an independent cohort of Polish recipient–donor pairs [19].
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In their first publication in 2015, the authors showed that graft
rs2735940 hTERT polymorphism was associated with a lower
risk of DGF. rs2630578 BICD1 and rs7235755 chromosome 18
polymorphisms in the graft were associated with higher serum
creatinine concentrations in the early period following KTx but
not with DGF. These results suggest a negative correlation be-
tween the length of telomeres and I/R injury severity [17]. In
2016, the same authors reported that the presence of chromo-
some 18 rs7235755 polymorphism in recipients was associated
with higher risk for DGF. Polymorphism in BICD1 in recipients
was also associated with higher serum creatinine concentra-
tions in long-term follow-up after KTx. Polymorphisms in hTERT
were not associated with kidney allograft outcomes [18]. In
2017, Kłoda et al. [19] studied 74 Polish deceased donor and re-
cipient pairs. Both donors’ and recipients’ rs2735940 hTERT TT
genotypes were associated with DGF but not with AR. The
rs2735940 hTERT TT donor genotype decreases the risk for DGF,
while the rs2735940 hTERT TT recipient genotype increases the
risk for DGF. DGF occurrence was five times higher for a CX (CT
or CC) donor genotype and TT recipient genotype. rs2630578
BICD1 and rs7235755 chromosome 18 polymorphisms in recipi-
ents or donors were not associated with either DGF or AR [19].
The limitation of telomere shortening in donors, as observed in
the case of rs2735940 hTERT polymorphism, is thus regarded as
protective against renal I/R injury.
Chemokines
Regulation of the interleukin-1 pathway: interleukin receptor
antagonist intron 2 polymorphism. The interleukin (IL)-1 path-
way is unique in having a natural inhibitor known as the IL-1 re-
ceptor antagonist (IL-1Ra). Manchanda et al. [20] studied 136
Indian KTRs from a related living donor and focused on three
polymorphisms in the IL-1 gene cluster: IL-1b promoter region
 511, IL-1b exon-5 and IL-1Ra in intron 2. Five alleles of the IL-1Ra
have been reported, corresponding to 2, 3, 4, 5 and 6 copies of an
86-base pair repeat located in intron 2. Genotype 1/2 (410/240) of
IL-1Ra was associated with a higher risk of DGF in this cohort. A
homozygous state of allele 2 is a greater producer of IL-1Ra than
the heterozygous or wild-type homozygous states. Therefore
genotype 1/2 of IL-1Ra may be considered as a ‘low producer’ of
IL-1Ra, which in turn cannot counteract the pro-inflammatory re-
sponse of IL-1 at the time of renal I/R injury [20].
Apoptosis and inflammation: tumour necrosis factor-a -308G>A
and IL-10 -1082G>A polymorphisms. Tumour necrosis factor-a
(TNF-a) and IL-10 play a crucial role in the pathogenesis of renal
I/R injury. Activated macrophages secrete TNF-a, which binds to
TNF receptors on cells, leading them to apoptosis. IL-10 appears
to limit and control inflammation [46]. Deletion of the IL-10
gene accelerates kidney graft AR in mice [47]. Mandegary et al.
[21] enrolled a prospective single-centre cohort of 100 Iranian
consecutive kidney recipient–donor pairs. Significant associ-
ations were found between donors’ TNF-a polymorphism -
308 G>A and the occurrence of DGF, as well as between the
combination of donors’ IL10 AA or GA and TNF-a AA or GA geno-
types and DGF [21]. McDaniel et al. [30] studied cytokine poly-
morphisms in 77 African American allograft recipients and 77
controls. TNF-a polymorphism in recipients was not associated
with either DGF nor AR [30]. Finally, Israni et al. [31] recruited
965 recipients of deceased donor kidneys from 512 donors.
Recipient’s ethnicities included African American, White, Asian
and Native American. Donor’s ethnicities were African
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statistically associated with DGF, although a positive trend was
observed [31].
Cell migration: CX3CR1 V249I polymorphism. Fractalkine, also
known as CX3CL1, is a member of the chemokine family that
acts as an adhesion molecule and as an extracellular chemo-
attractant promoting cell migration [48]. Dabrowska-Zamojcin
et al. [22] enrolled 270 Caucasian KTRs to study the impact of
polymorphism V249I (rs3732379) in the Fractalkine receptor gene,
CX3CR1. This polymorphism has been associated with a reduced
number of CX3CL1 binding sites, reduced cell adhesion and
decreased signalling and chemotaxis. The rs3732379 CC genotype
in KTRs was associated with an increased risk for DGF [22].
T-cell homeostasis (CTLA-4 pathway)
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is expressed at the
surface of activated CD8 and CD4 T cells. It plays an inhibitory
role in inflammation and helps maintain peripheral tolerance
by suppressing T-cell proliferation and by inducting apoptosis
of activated T-cells [24]. Domanski et al. [23] enrolled 269
Caucasian KTRs to study the impact of rs231775 (þ49 A>G)
polymorphism in CTLA4 and found an association with the G al-
lele in rs231775 and a higher risk of DGF [23]. Similarly, Misra et
al. [24] enrolled 350 Indian patients with end-stage renal disease
(ESRD) and 350 controls. Among the 350 ESRD patients, 190
underwent KTx. The CTLA-4 variants rs231775, rs3087243 and
30-UTR dinucleotide AT repeats in recipients were involved in
genetic susceptibility to DGF. The A allele in both rs231775
(þ49 A>G) and rs3087243 was considered as protective against
DGF, while the G allele was associated with a higher risk of DGF.
Concerning 30-UTR dinucleotide AT repeats, the 102-bp allele
was protective against DGF, while 110-bp and 116-bp alleles
increased the risk for DGF [24].
Regulation of the immune response
The toll-like receptor (TLR) system is key in the innate immune
system and participates in both acute and chronic allograft dys-
function [25, 49]. Loss-of-function mutations of TLR4 in donors
have been associated with improved immediate kidney allograft
outcomes [50]. Therefore, Kru¨ger et al. [25] hypothesized that
genetic variations in the TLR system may affect clinical out-
come after KTx, including DGF. They enrolled 265 German KTRs
to evaluate the impact of selected polymorphisms in the TLR2,
TLR3, TLR4, TLR5, TLR9 and CD14 genes. The study showed that
the TLR3 F412L polymorphism had a significantly higher rate of
DGF in a univariate analysis but was not statistically significant
after adjusting for known risk factors of DGF. Every other poly-
morphism tested had no significant association with DGF [25].
Epoxieicosatrienoic acids (EETs) are vasodilatory factors with
anti-inflammatory properties. They may play a protective role
against I/R-related damage [51, 52]. Several cytochrome P450
(CYP450) isoforms mediate the biosynthesis of EETs [53]. In
humans, CYP2J2 and CYP2C8 are the most important isoforms.
CYP2J2*7 (rs890293) and CYP2C8*3 (rs10509681) are the most com-
mon variants affecting enzymatic activity in Caucasians [26].
Gervasini et al. [26] studied these polymorphisms in 166 consecu-
tive Caucasian adult KTRs. CYP2C8*3, which caused decreased
enzymatic activity and lower production of EETs, was associated
with a higher incidence of DGF in this cohort [26].
Ficolin (FCN)-2 is an activator of the complement system via
the lectin pathway. Complement activation plays a substantial
role in I/R injury at the time of KTx [27, 39]. The FCN-2 rs7851696
T allele is known to be associated with increased affinity of
lectin-2 for carbohydrate structures presented by different
pathogens [54]. Dabrowska-Zamojcin et al. [27] enrolled 270
Caucasian deceased-donor KTRs to evaluate the impact of
FCN-2 gene rs7851696, rs17549193 and rs4521835 polymorph-
isms in DGF, as well as in AR and chronic allograft dysfunction.
The results showed an increased risk for DGF and AR in case of
FCN-2 rs7851696 T allele, although these statistical associations
were not significant after Bonferroni correction [27].
Finally, nitric oxide (NO) plays a critical role in vascular tone
and host defence [40, 28]. There are two distinct forms of NO
synthases (NOSs): constitutive endothelial NOS (eNOS) and in-
ducible NOS (iNOS). eNOS helps in tissue reperfusion and recov-
ery after ischaemia and may reduce oxidative stress [28].
Dutkiewicz et al. [28] enrolled 187 polish KTRs to study the im-
pact of polymorphisms of the eNOS gene (G894T substitution
within exon 7 and intron 4 VNTR) on DGF, AR and chronic rejec-
tion and found an association between the a allele of the eNOS
intron 4 VNTR polymorphism and a higher risk for DGF [28].
DISCUSSION
Among 30 studies in the literature, 16 reports suggest an associ-
ation between polymorphisms and the occurrence of DGF
(Table 1), whereas 14 papers failed to find any relationship
(Table 2). As discussed below, it is interesting to note that genes
implicated in similar I/R-related pathways may or may not be
involved in genetic susceptibility to DGF. Hence several genes
connected to oxidative stress have been studied. I/R-related
ROS cause deleterious effects on kidney allografts by triggering
inflammatory injuries [13, 14]. High-producer polymorphisms in
genes coding for antioxidant proteins have been associated
with a lower risk of DGF, such as the presence of the -262 T allele
in the KTR CATALASE gene [15] or the presence of the B allele in
GSTM1 (GSTM1*B) in kidney donors [13]. In contrast, low-
producer polymorphisms have been shown to be deleterious in
I/R injury, including rs1695 genotype GG in GSTP1 in KTRs [14].
Furthermore, high-producer polymorphisms in genes coding for
pro-oxidant proteins have been associated with a higher risk of
DGF, like NADPH oxidase p22(phox) 242 T allele (CTþTT) in KTRs
[16]. Still, other reports focusing on the oxidative cascade failed
to link gene polymorphisms and DGF. As an example,
239þ 34 A/C and 47 C/T polymorphisms in the SOD1 and SOD2
genes were not associated with DGF development (Table 2) [29].
Superoxide dismutases (SODs) are regarded as the most import-
ant enzymes against ROS, particularly against superoxide anion
radicals.
Kidney aging may be notably reflected by telomere length
[17, 19, 55], and in the case of KTx, assessment of telomere
length in the early post-transplant period allows prediction of
allograft long-term outcomes [56]. In case of renal graft I/R, a
significant decrease in telomere length has been reported, thus
suggesting accelerated kidney senescence [17, 44]. Conversely,
limitation of telomere shortening in recipients may favour the
deleterious immune response [45]. Hence polymorphisms
rs2735940 hTERT (leading to limited telomere shortening) in
donors was associated with a lower risk for DGF [17, 19].
However, this very same genotype in recipients was associated
with increased risk for DGF, most probably due to an amplified
immune trigger [19]. Such a condition exemplifies the import-
ance of distinguishing the donor from the recipient genotype at
the time of studying genetic susceptibility to renal I/R.
Polymorphisms involved in I/R severity may be particularly
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relevant in donors, whereas polymorphisms implicated in AR
and inflammation may rather concern the recipients.
Renal I/R triggers inflammation, which in turn favours cyto-
kine/chemokine secretion [22, 21, 31]. TNF-a is a pro-apoptotic
cytokine. High-producer polymorphism of the TNF-a gene (i.e.
donor’s AA or GA at -308 G>A) appears to be deleterious and
associated with a higher risk for DGF [21]. Similarly, the combin-
ations of donors’ IL10 AA or GA and TNF-a AA or GA genotypes
were linked to DGF development, whereas TNF-a polymorph-
isms in recipients were not associated with DGF [21, 30, 31]. In
contrast, low-producer polymorphism of the TNF-a gene
(donor’s GG at -308 G>A) has been associated with a lower risk
for DGF [21]. However, this association between the donor’s
TNF-a gene polymorphisms and the occurrence of DGF failed to
be confirmed in a large cohort including 512 African American
and White donors [31]. Besides TNF-a, other cytokines have
been genetically studied in DGF susceptibility, including IL-2
[35, 30], IL-12 [33], transforming growth factor-b [31, 30, 21] and
IL-16 and IL-18 [36]. None of these studies found an association
with DGF susceptibility (Table 2). Conversely, polymorphisms of
genes coding for cytokine receptors may enhance their re-
sponse to stimulation. Hence the CC genotype of rs3732379
polymorphism (V249I) of CX3CR1 in recipients has been associ-
ated with an increased risk for DGF. CX3CR1 is the receptor of
CX3CL1, which is a chemokine acting as an adhesion molecule
and as an extracellular chemoattractant promoting cell migra-
tion. V249I polymorphism causes changes in the number of
CX3CL1 binding sites, thereby favouring cell adhesion, signal-
ling and chemotaxis [22]. Similarly, inflammation modulators
like CTLA-4, ETT and TLR may also attenuate or aggravate I/R
injury. High-producer polymorphisms of CTLA-4 [A allele in re-
cipients’ rs231775 (þ49 A>G) and rs3087243, as well as the 102-
bp allele in 30-UTR dinucleotide AT repeats] may prevent DGF.
CTLA-4 is expressed on activated CD8 and CD4 T-cells and helps
maintain homeostasis by downregulating T-cells [24]. In con-
trast, since EETs possess vasodilatory and anti-inflammatory
properties [26], low-producer polymorphisms in the CYP2C8
gene in recipients may increase the risk for post-transplant
DGF. The TLRs have a pivotal role in the innate immune system
and possess pro-inflammatory properties. The TLR3 F412L poly-
morphism has been associated with a higher risk of DGF [25], so
this polymorphism likely attenuates the function of TLR3.
Focusing on the complement cascade at the time of renal
I/R, Michielsen et al. [39] recently summarized the impact of
complement polymorphisms on kidney graft outcomes without
detailing their influence on DGF occurrence. Dabrowska-
Zamojcin et al. [27] more recently reported an association be-
tween the FCN-2 rs7851696 T allele and a higher risk of DGF—al-
though this association was significant only without correction
for multiple comparisons. The complement system, as part of
the innate immune system, is involved in protection against
foreign organisms and the clearance of apoptotic cells.
However, complement cascade may also aggravate I/R injury
via antibody binding, which eventually leads to poor outcomes
after KTx. In particular, a crucial role is suspected for mannose
binding lectin (MBL) in the early pathophysiology of renal I/R
[39]. Nevertheless, there was no significant difference in the in-
cidence of DGF in recipients with low MBL levels (400 ng/mL)
compared to those with high MBL levels [57]. C3 is the central
component of complement cascade and can be activated by
all three complement pathways. In mice, the absence of
local renal C3 in donor kidney significantly improves early
post-reperfusion injury [58]. In humans, the C3F allotype in both
donors and recipients was not associated with DGF [58].
The pathophysiology of DGF is complex and multifactorial,
including immunological and non-immunological factors [8, 7].
Furthermore, there might be additive actions of both I/R and AR
in the immediate post-transplant period, which may synergistic-
ally predispose to DGF. The actual role of genetic susceptibility to
renal I/R may thus be difficult to appropriately ‘quantify’ [30].
Genome-wide association studies (GWASs) are currently on-
going to test additional genes and SNPs in the particular settings
of DGF. Confirmatory clinical trials are also required in validation
cohorts. As an example, two SNPs (rs3811321 and rs6565887 on
chromosomes 14 and 18, respectively) have been initially identi-
fied by GWASs in 300 KTRs as predictive of serum creatinine lev-
els and hard clinical outcomes. However, Pihlstrøm et al. [59]
failed to confirm such an association between these two poly-
morphisms and post-transplant outcomes in 1638 recipients.
Indeed, conflicting data may result from the number of recruited
patients and from their ethnicity. Polymorphisms in the TNF-a
gene in 100 Iranian donors were associated with DGF occurrence
[21] but failed to be confirmed in a large cohort including 512
African American and White donors [31].
African American recipients have shown a higher risk of
DGF [60, 61]. Black ethnicity in recipients is a risk factor for DGF
[62], which is part of the nomogram established by Irish et al.
[63] for predicting the likelihood of DGF. Nevertheless,
Palanisamy et al. [61] showed that cardiovascular risk factors
contribute to disparities in graft outcomes in African American
KTRs. Furthermore, after correcting for cardiovascular risk fac-
tors, race per se did not show an independent effect on graft out-
comes [61].
In conclusion, several polymorphisms in either the donor or
the recipient or both have been associated with DGF in KTRs.
These polymorphisms are involved in oxidative stress, telomere
length, cytokine secretion and modulation, immunity and in-
flammation. These processes are involved in I/R injury, which is
regarded as one of the most important causes of DGF.
Identifying the polymorphisms linked to renal I/R may allow us
to better understand its pathophysiology and find new thera-
peutic targets.
The present review highlights the state of knowledge in the
field of genetic susceptibility to renal I/R. Although SNPs may
only have minor impacts per se on gene expression and protein
function, interactions among multiple SNPs may have a major
impact on molecular cascades [39]. Additionally, some SNPs
show very low frequency [31]. Validation studies are lacking or
inadequately powered for most SNPs studied thus far [39],
which may explain the controversial observations [21, 31].
Replication studies will need to include multivariate analyses to
isolate the putative effects of SNPs among other well-
established risk factors of DGF. Most importantly, one must
clearly distinguish the impact of SNPs in donors versus in re-
cipients versus in both. Polymorphisms involved in I/R severity
may be particularly relevant in donors, whereas polymorphisms
implicated in AR and inflammation may rather concern recipi-
ents [19]. Therefore, prospective multicentric studies including
patients of various genetic backgrounds are required to clinic-
ally determine the benefits (and harms) of genotyping donors
and recipients before KTx [59, 12].
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